Memantine for Agitation and Aggression in Severe Alzheimer's Disease

PHASE4CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2010

Conditions
Alzheimer's Disease
Interventions
DRUG

memantine

Following the baseline visit, subjects will receive memantine 5 mg OD for one week, followed by 5 mg BID for one week, followed by 10 mg QAM and 5 mg QPM for one week, followed by 10 mg BID for the following 9 weeks.

Trial Locations (2)

M2K 1E1

North York General Hospital, Toronto

M4N 3M5

Sunnybrook Health Sciences Centre, Toronto

All Listed Sponsors
collaborator

Lundbeck Canada Inc.

INDUSTRY

lead

Sunnybrook Health Sciences Centre

OTHER

NCT00401167 - Memantine for Agitation and Aggression in Severe Alzheimer's Disease | Biotech Hunter | Biotech Hunter